Table A3.
Association of BRAF or TERT C228T Promoter Mutation With PTC Recurrence
| Tumor Type and Mutation Status | Recurrence |
Recurrence per 1,000 Person-Years | 95% CI | Unadjusted |
Adjusted* |
Adjusted† |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | No. | % | Hazard Ratios | 95% CI | Hazard Ratios | 95% CI | Hazard Ratios | 95% CI | |||
| All PTC | |||||||||||
| BRAF V600E | |||||||||||
| Negative | 30 | 313 | 9.6 | 22.88 | 16.00 to 32.72 | 1.00 | 1.00 | 1.00 | |||
| Positive | 50 | 194 | 25.8 | 77.60 | 58.81 to 102.38 | 3.22 | 2.05 to 5.07 | 3.02 | 1.91 to 4.77 | 1.51 | 0.87 to 2.60 |
| TERT C228T | |||||||||||
| Negative | 51 | 446 | 11.4 | 30.21 | 22.96 to 39.74 | 1.00 | 1.00 | 1.00 | |||
| Positive | 29 | 61 | 47.5 | 108.55 | 75.43 to 156.20 | 3.46 | 2.19 to 5.45 | 3.21 | 2.02 to 5.09 | 1.78 | 0.97 to 3.25 |
| CPTC | |||||||||||
| BRAF V600E | |||||||||||
| Negative | 22 | 219 | 10.0 | 23.82 | 15.69 to 36.18 | 1.00 | 1.00 | 1.00 | |||
| Positive | 42 | 164 | 25.6 | 77.48 | 57.26 to 104.84 | 3.10 | 1.85 to 5.20 | 2.88 | 1.71 to 4.86 | 1.46 | 0.77 to 2.75 |
| TERT C228T | |||||||||||
| Negative | 40 | 336 | 11.9 | 32.06 | 23.52 to 43.71 | 1.00 | 1.00 | 1.00 | |||
| Positive | 24 | 47 | 51.1 | 110.18 | 73.85 to 164.38 | 3.32 | 2.00 to 5.52 | 3.15 | 1.89 to 5.24 | 1.54 | 0.76 to 3.12 |
NOTE. Hazard ratios and 95% CIs were calculated with Cox regression.
Abbreviations: CPTC, conventional papillary thyroid cancer; PTC, papillary thyroid cancer.
*
Adjustment was made for patient age at diagnosis and sex.
†
Adjustment was made for patient age at diagnosis, sex, multifocality, tumor size, extrathyroidal invasion, vascular invasion, and lymph node metastasis.